RCT: First-line nivolumab plus chemotherapy vs. chemotherapy alone for advanced gastric, gastro-esophageal junction, and esophageal adenocarcinoma.

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter (thread – click for more)

#Nivolumab plus chemotherapy shows superior OS, PFS benefit, and acceptable safety profile—compared to chemotherapy alone—in previously untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma.

? https://t.co/0u9R5ZIwd2, by @YJanjigianMD et al.

— The Lancet (@TheLancet) July 8, 2021